Accordingly, inhibition of the CX3CL1/CX3CR1 system by neutralizing antibody of CX3CL1 or silencing of CX3CR1 or SGLT2i may represent a novel therapeutic strategy for improving cardiorenal dysfunction in diabetes. The gene discussed is CX3CR1; the disease is diabetes mellitus.